Clinical Trials Browser

Completed × Interventional × Epirubicin × Clear all

NCT00872625 2026-04-23

Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT04433156 2026-04-09

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Completed

Lymphoma, B-Cell, Marginal Zone

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

Triple Negative Breast Neoplasms

NCT00066443 2026-03-27

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Phase 1/2 Completed

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT01358877 2025-11-28

APHINITY

Phase 3 Completed

4,804 enrolled 45 charts 1 FDA

Breast Neoplasms

NCT04214626 2025-11-19

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03036488 2025-10-29

MK-3475-522

Phase 3 Completed

1,174 enrolled 1 FDA

Triple Negative Breast Neoplasms

NCT01630083 2025-06-15

FAST

Phase 2 Completed

Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

Breast Neoplasms

NCT03356860 2024-11-20

B-IMMUNE

Phase 1/2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03013504 2024-11-06

TROIKA

Phase 3 Completed

Breast Neoplasms

NCT03355157 2024-10-01

PADMA

Phase 4 Completed

Breast Neoplasms, Patient Acceptance of Health Care

NCT03277924 2024-08-13

ImmunoSarc

Phase 1/2 Completed

Chondrosarcoma, Extraskeletal Myxoid, Bone Neoplasms, Chondrosarcoma, Hemangioendothelioma, Hemangiosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03272477 2024-04-17

TP-II

Phase 2 Completed

Breast Neoplasms

NCT06309732 2024-03-13

GAMEC-II

Phase 2 Completed

Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms

NCT00630032 2024-02-21

TavIx

Phase 3 Completed

762 enrolled 14 charts

Breast Neoplasms

NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Phase 1 Completed

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

NCT02287129 2023-11-28

MEMORI

Phase 2 Completed

Gastrointestinal

Adenocarcinoma of the Esophagogastric Junction

NCT00525759 2023-11-24

ANZAC

Phase 2 Completed

Breast Neoplasms

NCT00432172 2023-04-03

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Phase 2 Completed

189 enrolled 17 charts

Breast Neoplasms

NCT00129935 2023-03-31

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Phase 3 Completed

1,384 enrolled 22 charts

Breast Neoplasms

NCT00841828 2023-03-31

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Phase 2 Completed

102 enrolled 10 charts

Breast Neoplasms

NCT01036087 2023-03-30

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Phase 2 Completed

47 enrolled 13 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00129922 2023-03-06

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00773695 2023-01-09

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT02549677 2022-10-27

ELEGANT

Phase 4 Completed

Breast Neoplasms

NCT01726452 2022-09-30

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Phase 3 Completed

Gastrointestinal

Esophageal Neoplasms

NCT00087178 2022-08-11

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Phase 3 Completed

2,722 enrolled 14 charts

Breast Neoplasms

NCT01966471 2022-06-14

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Phase 3 Completed

1,846 enrolled 19 charts

Breast Neoplasms

NCT02050919 2022-03-21

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

Phase 2 Completed

20 enrolled 14 charts

Sarcoma

NCT02400567 2022-03-15

NeoPAL

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

NCT03556358 2022-01-14

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3 Completed

809 enrolled 14 charts

Breast Neoplasms

NCT00193206 2021-11-23

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Phase 2 Completed

123 enrolled 8 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00193050 2021-10-26

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Phase 2 Completed

110 enrolled 8 charts

Breast Neoplasms

NCT02395640 2021-10-26

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT00464646 2021-10-25

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Phase 2 Completed

105 enrolled 17 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00381706 2021-09-29

Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Phase 2 Completed

245 enrolled 15 charts

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02742051 2021-09-23

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01593020 2021-09-22

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Phase 2 Completed

54 enrolled 10 charts

Breast Neoplasms

NCT02132949 2021-09-17

BERENICE

Phase 2 Completed

401 enrolled 24 charts

Breast Neoplasms

NCT02909751 2021-05-20

NeoToc

Phase 2 Completed

Breast Neoplasms

NCT03289819 2021-04-08

NIB

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02128243 2021-03-26

MATEO

Phase 2 Completed

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT00003606 2021-02-21

Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 3 Completed

Lung Neoplasms

NCT02324088 2021-02-21

PEGASE07

Phase 3 Completed

Inflammatory Breast Neoplasms

NCT02685059 2021-02-15

GeparNuevo

Phase 2 Completed

Breast Neoplasms

NCT01690702 2021-02-02

GAIN-2

Phase 3 Completed

Breast Neoplasms

NCT02682693 2021-02-02

GeparX

Phase 2 Completed

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT04659551 2020-12-09

GIADA

Phase 2 Completed

Breast Neoplasms

NCT00309569 2020-10-14

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Phase 3 Completed

Breast Neoplasms